(BMY) Bristol-Myers Squibb - Ratings and Ratios
Oncology, Hematology, Immunology, Cardiovascular, Neurology
BMY EPS (Earnings per Share)
BMY Revenue
Description: BMY Bristol-Myers Squibb September 25, 2025
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells prescription medicines across therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience.
The firm’s flagship products include Eliquis (anticoagulant for atrial fibrillation and VTE), Opdivo (PD-1 checkpoint inhibitor for multiple cancers), Pomalyst and Imnovid (for multiple myeloma), Orencia (for rheumatoid and psoriatic arthritis), and Sprycel (for Philadelphia-chromosome-positive CML). Additional marketed assets span Yervoy and Opdualag (melanoma), Empliciti and Abecma (multiple myeloma), Reblozyl (anemia), Breyanzi (large B-cell lymphoma), Cobenfy (schizophrenia), Krazati (KRAS-G12C NSCLC), Camzyos (obstructive HCM), Sotyktu (plaque psoriasis), Augtyro (ROS1-positive NSCLC), Revlimid (multiple myeloma), and Abraxane (breast, NSCLC, pancreatic cancer). Products are sold through wholesalers, distributors, pharmacies, hospitals, clinics, and government agencies.
Founded in 1887 and headquartered in Princeton, New Jersey, BMY was previously known as Bristol-Myers Company. The company’s revenue in FY 2023 was approximately $45.6 billion, with R&D expenditures of about $10.5 billion, reflecting its commitment to pipeline expansion. Recent drivers of the sector include an aging global population increasing demand for chronic-disease therapies, and heightened pricing scrutiny in the United States that can affect margin trajectories.
Assumption: FY 2023 financials are taken from the latest 10-K filing; uncertainty remains around upcoming patent expirations for Eliquis and potential competitive pressure from biosimilars in oncology, which could materially affect future cash flows.
For a data-rich, quantitative deep-dive on BMY’s valuation sensitivities and scenario analysis, you might find ValueRay’s platform worth exploring.
BMY Stock Overview
| Market Cap in USD | 89,213m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1972-01-01 |
BMY Stock Ratings
| Growth Rating | -58.2% |
| Fundamental | 74.9% |
| Dividend Rating | 61.3% |
| Return 12m vs S&P 500 | -23.4% |
| Analyst Rating | 3.37 of 5 |
BMY Dividends
| Dividend Yield 12m | 5.44% |
| Yield on Cost 5y | 5.06% |
| Annual Growth 5y | 1.18% |
| Payout Consistency | 91.5% |
| Payout Ratio | 36.9% |
BMY Growth Ratios
| Growth Correlation 3m | -67.6% |
| Growth Correlation 12m | -80.5% |
| Growth Correlation 5y | -43.2% |
| CAGR 5y | -12.87% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.27 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.47 |
| Sharpe Ratio 12m | 0.42 |
| Alpha | -18.14 |
| Beta | 0.344 |
| Volatility | 22.28% |
| Current Volume | 41931.6k |
| Average Volume 20d | 15379.2k |
| Stop Loss | 44.2 (-3.1%) |
| Signal | 2.29 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (5.05b TTM) > 0 and > 6% of Revenue (6% = 2.86b TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 1.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.94% (prev 7.79%; Δ 4.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 15.90b > Net Income 5.05b (YES >=105%, WARN >=100%) |
| Net Debt (38.33b) to EBITDA (15.09b) ratio: 2.54 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.04b) change vs 12m ago 0.44% (target <= -2.0% for YES) |
| Gross Margin 61.74% (prev 56.12%; Δ 5.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.39% (prev 49.14%; Δ 1.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.33 (EBITDA TTM 15.09b / Interest Expense TTM 1.98b) >= 6 (WARN >= 3) |
Altman Z'' 1.76
| (A) 0.06 = (Total Current Assets 33.22b - Total Current Liabilities 27.53b) / Total Assets 94.68b |
| (B) 0.17 = Retained Earnings (Balance) 16.15b / Total Assets 94.68b |
| (C) 0.09 = EBIT TTM 8.57b / Avg Total Assets 94.66b |
| (D) 0.19 = Book Value of Equity 14.89b / Total Liabilities 77.19b |
| Total Rating: 1.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.91
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 11.43% = 5.0 |
| 3. FCF Margin 30.56% = 7.50 |
| 4. Debt/Equity 2.92 = -0.65 |
| 5. Debt/Ebitda 2.54 = -1.03 |
| 6. ROIC - WACC (= 4.64)% = 5.80 |
| 7. RoE 29.57% = 2.46 |
| 8. Rev. Trend 63.84% = 4.79 |
| 9. EPS Trend -9.21% = -0.46 |
What is the price of BMY shares?
Over the past week, the price has changed by +4.08%, over one month by +4.75%, over three months by +0.58% and over the past year by -9.06%.
Is Bristol-Myers Squibb a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMY is around 42.12 USD . This means that BMY is currently overvalued and has a potential downside of -7.67%.
Is BMY a buy, sell or hold?
- Strong Buy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.1 | 16.3% |
| Analysts Target Price | 53.1 | 16.3% |
| ValueRay Target Price | 45.4 | -0.4% |
BMY Fundamental Data Overview October 28, 2025
P/E Trailing = 17.6382
P/E Forward = 7.5815
P/S = 1.8701
P/B = 5.3387
P/EG = 2.2562
Beta = 0.344
Revenue TTM = 47.70b USD
EBIT TTM = 8.57b USD
EBITDA TTM = 15.09b USD
Long Term Debt = 44.47b USD (from longTermDebt, last quarter)
Short Term Debt = 4.91b USD (from shortTermDebt, last quarter)
Debt = 50.93b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 38.33b USD (from netDebt column, last quarter)
Enterprise Value = 127.54b USD (89.21b + Debt 50.93b - CCE 12.60b)
Interest Coverage Ratio = 4.33 (Ebit TTM 8.57b / Interest Expense TTM 1.98b)
FCF Yield = 11.43% (FCF TTM 14.58b / Enterprise Value 127.54b)
FCF Margin = 30.56% (FCF TTM 14.58b / Revenue TTM 47.70b)
Net Margin = 10.58% (Net Income TTM 5.05b / Revenue TTM 47.70b)
Gross Margin = 61.74% ((Revenue TTM 47.70b - Cost of Revenue TTM 18.25b) / Revenue TTM)
Gross Margin QoQ = 65.78% (prev 65.53%)
Tobins Q-Ratio = 1.35 (Enterprise Value 127.54b / Total Assets 94.68b)
Interest Expense / Debt = 0.95% (Interest Expense 485.0m / Debt 50.93b)
Taxrate = 25.94% (460.0m / 1.77b)
NOPAT = 6.35b (EBIT 8.57b * (1 - 25.94%))
Current Ratio = 1.21 (Total Current Assets 33.22b / Total Current Liabilities 27.53b)
Debt / Equity = 2.92 (Debt 50.93b / totalStockholderEquity, last quarter 17.43b)
Debt / EBITDA = 2.54 (Net Debt 38.33b / EBITDA 15.09b)
Debt / FCF = 2.63 (Net Debt 38.33b / FCF TTM 14.58b)
Total Stockholder Equity = 17.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.33% (Net Income 5.05b / Total Assets 94.68b)
RoE = 29.57% (Net Income TTM 5.05b / Total Stockholder Equity 17.08b)
RoCE = 13.93% (EBIT 8.57b / Capital Employed (Equity 17.08b + L.T.Debt 44.47b))
RoIC = 9.53% (NOPAT 6.35b / Invested Capital 66.65b)
WACC = 4.89% (E(89.21b)/V(140.14b) * Re(7.28%) + D(50.93b)/V(140.14b) * Rd(0.95%) * (1-Tc(0.26)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.12%
[DCF Debug] Terminal Value 78.97% ; FCFE base≈13.92b ; Y1≈14.60b ; Y5≈17.04b
Fair Price DCF = 146.8 (DCF Value 298.80b / Shares Outstanding 2.04b; 5y FCF grow 5.25% → 3.0% )
EPS Correlation: -9.21 | EPS CAGR: -10.65% | SUE: 1.42 | # QB: 2
Revenue Correlation: 63.84 | Revenue CAGR: 3.31% | SUE: 2.00 | # QB: 7
Additional Sources for BMY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle